Phase 1/2 Trial Begins on ONCOS-102, Imfinzi Combination in Advanced Ovarian, Colorectal Cancers

Phase 1/2 Trial Begins on ONCOS-102, Imfinzi Combination in Advanced Ovarian, Colorectal Cancers
A new Phase 1/2 clinical trial has been launched testing a combination of investigational viral therapy ONCOS-102 and Imfinzi (durvalumab) in patients with advanced ovarian and colorectal cancers. The open-label trial (NCT02963831) has already enrolled and evaluated the first group of patients, and is continuing to recruit as many as 78 patients at multiple centers across

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *